Paolo Bigini, Elisa R. Zanier, Silvia Saragozza, Simona Maciotta, Pietro Romele, Patrizia Bonassi Signoroni, Antonietta Silini, Francesca Pischiutta, Eliana Sammali, Claudia Balducci, Martina B. Violatto, Laura Talamini, David Garry, Davide Moscatelli, Raffaele Ferrari, Mario Salmona, Maria Grazia De Simoni, Federico Maggi, Giuseppe Simoni, Francesca Romana Grati, Ornella Parolini.
1IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, Italy.
2R&D Unit, TOMA Advanced Biomedical Assays S.p.A., Busto Arsizio, Varese, Italy.
3Centro di Ricerca “E. Menni”, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
4Fondazione IRCCS-Istituto Neurologico Carlo Besta, Milan, Italy.
5Centre for BioNano Interactions, School of Chemistry and Chemical Biology, University College Dublin, Belfield, Dublin, Ireland.
6Department of Chemistry, Material and Chemical Engineering, “Giulio Natta” Politecnico di Milano, Milan, Italy.
7Institute for Chemical and Bioengineering, ETH Zurich, Zurich, Switzerland
J Cell Mol Med. 2016 Jun;20(6):1036-48
Il laboratorio TOMA in collaborazione con l’Istituto di ricerche farmacologiche “Mario Negri” e il Centro di ricerca “E. Menni” pubblica i risultati dello studio di nanotraccianti in cellule staminali mesenchimali derivanti da villi coriali al terzo trimestre e placenta a termine.
Con questo studio si è determinata la potenzialità di questi nanotraccianti nello studio di trapianti di cellule staminali in vivo. Infatti, essi non alterano sia le caratteristiche fenotipiche e genotipiche sia gli effetti immunomodulatori in vitro ed in vivo delle cellule staminali mesenchimali di origine placentare. Questo permette di seguire il percorso delle cellule una volta iniettate in vivo come cura per malattie neurodegenerative. In conclusione, i nanotraccianti studiati possono essere utilizzati per capire in che modo agiscono le cellule staminali mesenchimali di origine placentare nel miglioramento degli effetti neurodegenerativi dati da ischemia cerebrale.
In the cell therapy scenario, efficient tracing of transplanted cells is essential for investigating cell migration and interactions with host tissues. This is fundamental to provide mechanistic insights which altogether allow for the understanding of the translational potential of placental cell therapy in the clinical setting. Mesenchymal stem/stromal cells (MSC) from human placenta are increasingly being investigated for their potential in treating patients with a variety of diseases. In this study, we investigated the feasibility of using poly (methyl methacrylate) nanoparticles (PMMA-NPs) to trace placental MSC, namely those from the amniotic membrane (hAMSC) and early chorionic villi (hCV-MSC). We report that PMMP-NPs are efficiently internalized and retained in both populations, and do not alter cell morphofunctional parameters. We observed that PMMP-NP incorporation does not alter in vitro immune modulatory capability of placental MSC, a characteristic central to their reparative/therapeutic effects in vitro. We also show that in vitro, PMMP-NP uptake is not affected by hypoxia. Interestingly, after in vivo brain ischaemia and reperfusion injury achieved by transient middle cerebral artery occlusion (tMCAo) in mice, iv hAMSC treatment resulted in significant improvement in cognitive function compared to PBS-treated tMCAo mice. Our study provides evidence that tracing placental MSC with PMMP-NPs does not alter their in vitro and in vivo functions. These observations are grounds for the use of PMMP-NPs as tools to investigate the therapeutic mechanisms of hAMSC and hCV-MSC in preclinical models of inflammatory-driven diseases.
Clicca qui per l’articolo completo